Dynamic Technology Lab Private Ltd boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 13.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 65,450 shares of the medical equipment provider’s stock after buying an additional 7,540 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Boston Scientific were worth $1,788,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Truewealth LLC acquired a new position in Boston Scientific during the fourth quarter valued at $116,000. Icon Wealth Partners LLC acquired a new position in Boston Scientific during the fourth quarter valued at $117,000. Delpha Capital Management LLC acquired a new position in Boston Scientific during the fourth quarter valued at $135,000. Ostrum Asset Management acquired a new position in Boston Scientific during the first quarter valued at $174,000. Finally, Summit Trail Advisors LLC raised its position in Boston Scientific by 3,853.8% during the first quarter. Summit Trail Advisors LLC now owns 194,923 shares of the medical equipment provider’s stock valued at $195,000 after buying an additional 189,993 shares during the period. 89.00% of the stock is currently owned by hedge funds and other institutional investors.
In related news, EVP David A. Pierce sold 5,000 shares of the stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $27.22, for a total transaction of $136,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Kevin J. Ballinger sold 31,056 shares of the stock in a transaction that occurred on Monday, May 7th. The shares were sold at an average price of $30.00, for a total value of $931,680.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 163,030 shares of company stock valued at $5,211,897. 0.73% of the stock is owned by corporate insiders.
BSX has been the topic of several research reports. Morgan Stanley upped their target price on Boston Scientific from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Monday, March 19th. Piper Jaffray Companies initiated coverage on Boston Scientific in a research report on Friday, February 23rd. They issued an “overweight” rating and a $31.00 target price on the stock. TheStreet lowered Boston Scientific from a “b” rating to a “c” rating in a research report on Monday, March 5th. Canaccord Genuity reaffirmed a “buy” rating and issued a $36.00 target price on shares of Boston Scientific in a research report on Wednesday, April 25th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $35.00 target price on shares of Boston Scientific in a research report on Tuesday, March 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $32.45.
Shares of NYSE BSX opened at $32.15 on Friday. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 0.68. The stock has a market cap of $44.47 billion, a PE ratio of 25.52, a P/E/G ratio of 2.30 and a beta of 0.77. Boston Scientific Co. has a 52 week low of $24.54 and a 52 week high of $37.30.
Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 25th. The medical equipment provider reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.32 by $0.01. The business had revenue of $2.38 billion for the quarter, compared to analyst estimates of $2.34 billion. Boston Scientific had a return on equity of 25.10% and a net margin of 1.21%. The firm’s revenue for the quarter was up 10.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.29 EPS. research analysts expect that Boston Scientific Co. will post 1.39 earnings per share for the current year.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.